Peripart um cardiomyopathy is defi ned as a dilated cardiomyopathy of unknown cause associated with pregnancy. It occurs in the last gestational month or in fi rst 5 months postpartum and is associated with no other cardiac disease [20] . Although this condition is relatively rare, its exact incidence is unclear (the reported incidence varies between 1 in 1,500 and 1 in 15,000 pregnancies), and the condition is more common among Africans and Haitians. It is associated with older maternal age, obesity, multiparity, multiple pregnancies, and pregnancy-induced hypertension. Th e patient typically presents with symptoms of congestive heart failure: dyspnea, orthopnea, shortness of breath on exertion, upper abdominal pain, and so on. Echocardiography demonstrates systolic dysfunction. Proposed pathogenic hypotheses for peripartum cardiomyopathy include viral myocarditis, auto-immunemediated injury, and prolonged tocolysis. Current evidence strongly suggests that the disease is triggered by a by-product of prolactin metabolism, resulting in unbalanced peri-/postpartum oxidative stress [21] . Th e hormone is proteolytically cleaved, and an antiangio-genic, proapoptotic, and proinfl ammatory 16-kDa byproduct appears to attack the myocardium [22] .